Profile picture of Matthew Links

Prof Matthew Links

Profile picture of Matthew Links

MBBS, PhD, MPhil (Higher ED), FRACP

Medical Oncologist
Call
Enquire
Referrals

Prof Matthew Links is committed to achieving the best possible outcomes for his patients. He combines a compassionate, calm approach with a strong interest in clinical research to ensure his patients are well-informed and supported throughout their treatment.

Biography

Prof Matthew Links is an experienced medical oncologist at Icon Cancer Centre Southport, bringing over 25 years’ experience in the diagnosis and treatment of a range of malignancies. Prof Links completed his Bachelor of Medicine, Bachelor of Surgery at Sydney University and commenced specialist oncology training in leading Sydney hospitals. He completed a PhD in cancer drug development at the University of New South Wales in 2000, followed by a fellowship at the Beatson Institute for Cancer Research in Glasgow. Prof Links subsequently worked as a staff specialist in medical oncology at St George Hospital (2000-2016) and was Director of Clinical Training at Gold Coast Hospital and Health Service.

Prof Links maintains a strong interest in education, quality improvement and clinical research, actively engaging in medical education and co-authoring journal articles in leading national and international medical publications. He is a Professor of Medicine at Bond University and held previous appointments as Professor of Medicine at Griffith University and Adjunct Professor of Education at Griffith Institute for Educational Research.

Prof Links is an active member of several leading medical associations including American Society of Clinical Oncology (ASCO), Medical Oncology Group of Australia and Clinical Oncological Society of Australia (COSA). He is also a fellow of the Royal Australasian College of Physicians (FRACP) and has held a position on the RACP Education Committee. His clinical experience covers a broad range of solid tumour malignancies, with special interest in breast cancer, prostate cancer, lung cancer, geriatric cancer care, integration of primary care with specialist cancer care and second opinions.

Publications

  • Finding common ground: meta-synthesis of communication frameworks found in patient communication, supervision and simulation literature. M. Links, L. Watterson, P. Martin, S. O’Regan & E. Molloy (2020). BMC Medical Education, 2020. 20(1). doi 10.1186/s12909-019-1922-2.

  • Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis. J. Man, G. Ritchie, M. Links, S. Lord, & C. Lee. Asia-Pacific Journal of Clinical Oncology, 2018. 14(4). doi 10.1111/ajco.12838.

  • Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. C. Lee, J. Man, S. Lord, W. Cooper, M. Links, V. Gebski, R. Herbst, R. Gralla, T. Mok, & J. Yang. JAMA Oncology, 2017. 4(2). doi 10.1001/jamaoncol.2017.4427.

  • Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC). M. Tang, J. Chen, D. Goldstein, M. Links, Matthew, S. Lord, I. Marschner, J. Simes, & C.Lee. Journal of Clinical Oncology, 2017. 35(4_suppl):227. doi 10.1200/JCO.2017.35.4_suppl.227.

Special Interests

Prof Matthew Links accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Geriatric oncology
  • Lung cancer
  • Prostate cancer

Languages spoken

  • English

Icon Locations

Affiliations & Memberships

  • American Society of Clinical Oncology (ASCO)
  • Clinical Oncology Society of Australia (COSA)
  • Medical Oncology Group of Australia (MOGA)
  • Royal Australasian College of Physicians (RACP)

Publications

  • Finding common ground: meta-synthesis of communication frameworks found in patient communication, supervision and simulation literature. M. Links, L. Watterson, P. Martin, S. O’Regan & E. Molloy (2020). BMC Medical Education, 2020. 20(1). doi 10.1186/s12909-019-1922-2.

  • Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis. J. Man, G. Ritchie, M. Links, S. Lord, & C. Lee. Asia-Pacific Journal of Clinical Oncology, 2018. 14(4). doi 10.1111/ajco.12838.

  • Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. C. Lee, J. Man, S. Lord, W. Cooper, M. Links, V. Gebski, R. Herbst, R. Gralla, T. Mok, & J. Yang. JAMA Oncology, 2017. 4(2). doi 10.1001/jamaoncol.2017.4427.

  • Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC). M. Tang, J. Chen, D. Goldstein, M. Links, Matthew, S. Lord, I. Marschner, J. Simes, & C.Lee. Journal of Clinical Oncology, 2017. 35(4_suppl):227. doi 10.1200/JCO.2017.35.4_suppl.227.

Search

Contact us
Become a patient